Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
Top Cited Papers
Open Access
- 1 March 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (5), 657-668
- https://doi.org/10.1086/499819
Abstract
The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investmeThis publication has 75 references indexed in Scilit:
- Challenges of Sexually Transmitted Disease Prevention and Control: No Magic Bullet, but Some Bullets Would Still Be AppreciatedClinical Infectious Diseases, 2005
- Lack of development of new antimicrobial drugs: a potential serious threat to public healthThe Lancet Infectious Diseases, 2005
- Antiinfective biotechs face partnering gapNature Biotechnology, 2005
- Taking inventory: antibacterial agents currently at or beyond Phase 1Current Opinion in Microbiology, 2004
- The Antibiotic Pipeline — Challenges, Costs, and ValuesThe New England Journal of Medicine, 2004
- Trends in Antimicrobial Drug Development: Implications for the FutureClinical Infectious Diseases, 2004
- Antimicrobial drug development – the past, the present, and the futureClinical Microbiology & Infection, 2004
- Antimicrobial Resistance Trends and Outbreak Frequency in United States HospitalsClinical Infectious Diseases, 2004
- Development of drugs for antimicrobial-resistant pathogensCurrent Opinion in Infectious Diseases, 2003
- Why is big Pharma getting out of antibacterial drug discovery?Current Opinion in Microbiology, 2003